When applied topically to the antigen injection site, Resiquimod acts as a TLR 7/8 agonist to stimulate immune activation as evidenced by Th1 cytokine production, enhanced antibody responses and CTL activation.
Demonstrated adjuvant activity
Toxicology and clinical data packages to support development available
Ability to enter Phase 1 studies quickly
Enhanced therapeutic window due to topical delivery
